Shire to present ADHD treatments scientific data

Follow us on Twitter

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington, D.C.

“Shire is committed to the advancement of ADHD research, and we are pleased to be presenting the efficacy and safety results from several studies of our ADHD treatments,” said Gwendolyn Niebler, Vice President of Global Medical Affairs at Shire. “We believe the physician community will find the lisdexamfetamine dimesylate, methylphenidate transdermal system and guanfacine extended release study findings to be presented at APA a relevant contribution to the growing body of research on our ADHD treatment options.”-Porter Novelli

harminka's picture

Posted May 2nd, 2008 by harminka

Receive HULIQ News in Email:

Subscribe in a reader